Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0028-1113692 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An online case-based radiology course improves veterinary students' day one competency in small animal radiographic interpretation.
Vet Rec
January 2025
Richard A. Gillespie College of Veterinary Medicine, Lincoln Memorial University, Harrogate, Tennessee, USA.
Background: Accurate radiographic interpretation is an important day one skill. A case-based radiology course (CBC) demonstrated better learning outcomes than a lecture-based course (LBC) immediately and after a one-semester period. The aim of this study was to compare long-term learning outcomes of both groups.
View Article and Find Full Text PDFsMAdCAM-1 is decreased after allo-HCT, along with gut microbiota dysbiosis, and is associated with hematopoietic recovery.
Hemasphere
January 2025
Sorbonne Université, Centre de Recherche Saint-Antoine (CRSA) INSERM UMRs938, Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP Paris France.
First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.
Clin Kidney J
January 2025
Department of General Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Stuttgart, Germany.
Background: Sparsentan, a dual-acting antagonist for both the angiotensin II receptor type 1 and the endothelin receptor type A, has emerged as a promising therapeutic agent for the treatment of IgA nephropathy (IgAN). Following the publication of the PROTECT trial, sparsentan recently received approval for the treatment of IgAN in Europe. However, it remains uncertain whether an additive effect can be observed in the context of existing treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors, given that the PROTECT study did not investigate this dual therapy approach.
View Article and Find Full Text PDFThree effective cases of transcatheter arterial embolization after atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a case report.
J Med Case Rep
January 2025
Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, 1-5-7, Asahimachi, Abeno-Ku, Osaka, 545-8585, Japan.
Background: The Barcelona Clinic Liver Cancer staging system classifies hepatocellular carcinoma on the basis of tumor characteristics, liver function, and Eastern Cooperative Oncology Group performance status. Hepatocellular carcinoma is divided into five stages, and the treatment options for intermediate-stage hepatocellular carcinoma have evolved in recent years. Transcatheter arterial chemoembolization remains the standard treatment for intermediate-stage (stage B) hepatocellular carcinoma.
View Article and Find Full Text PDFAdvances in personalized medicine and Systems Biology have introduced probabilistic models and error discovery to cardiovascular care, aiding disease prevention and procedural planning. However, clinical application faces cultural, technical, and methodological hurdles. Patient autonomy remains essential, with shared decision-making (SDM) gaining importance in managing complex cardiovascular treatment options.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!